Immune responses in pancreatic cancer may be restricted byprevalence of activated regulatory T-cells, dysfunctionalCD8+ T-cells, and senescent T-cells
S. Sivakumar, E. Abu-Shah, D. Ahern, E. H. Arbe-Barnes, N. Mangal, S. Reddy, A. Rendek, A. Easton, E. Kurz, M. Silva, L. R. Heij, Z. Soonawalla, R. Bashford-Rogers, M. R. Middleton, M. Dustin
Abstract
Pancreatic cancer has the worst prognosis of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better therapeutic strategies. In this study, we analysed 32 human pancreatic cancer patients from two independent cohorts. A multi-parameter mass-cytometry analysis was performed on 32,000 T-cells from eight patients. Single-cell RNA sequencing dataset analysis was performed on a cohort of 24 patients. Multiplex immunohistochemistry imaging and spatial analysis were performed to map immune infiltration into the tumour microenvironment. Regulatory T-cell populations demonstrated highly immunosuppressive states with high TIGIT, ICOS and CD39 expression. CD8+ T-cells were found to be either in senescence or an exhausted state. The exhausted CD8 T-cells had low PD-1 expression but high TIGIT and CD39 expression. These findings were corroborated in an independent pancreatic cancer single-cell RNA dataset from additional 24 patients. These data suggest that T-cells are major players in the suppressive microenvironment of pancreatic cancer. Our work identifies novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion
R. Ajina, A. Zuo, … L. M. Weiner·bioRxiv·Jun 15, 2020
- Interleukin 6 drives durable T cell-mediated immunity to pancreatic cancer
Paige C. Arneson‐Wissink, Alexandra Q. Bartlett, … Aaron J. Grossberg·Cellular and Molecular Gastroenterology and HepatologyPeer-reviewed·Jan 1, 2026
- TNFR2 blockade promotes anti-tumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
Anaïs Debesset, Caroline Pilon, … José Laurent Cohen·Journal for ImmunoTherapy of CancerPeer-reviewed·Nov 1, 2024
- Functional T cells trapped behind a stromal wall: a Brake-with-Wall phenotype redefines pancreatic adenocarcinoma immunotherapy resistance
Jeongsoon Yong·bioRxiv·May 14, 2026
- PIK3CA in KrasG12D/Trp53R172H Tumor Cells Promotes Immune Evasion by Limiting Infiltration of T Cells in a Model of Pancreatic Cancer
Nithya Sivaram, Patrick A. McLaughlin, … Richard Z. Lin·bioRxiv·Jan 15, 2019
- Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer
Cody L. Wolf, Roxanne K. Ruiz, … Kimberly A. Kelly·Frontiers in ImmunologyPeer-reviewed·Aug 17, 2026